Experimental HCV Drugs
Experimental HCV Drugs
AASLD 2011: Daclatasvir with Pegylated Interferon/ Ribavirin Produces High Rates of HCV Suppression
- Details
- Category: HCV Treatment
- Published on Tuesday, 06 December 2011 00:00
- Written by Liz Highleyman
Most treatment-naive chronic hepatitis C patients who added the experimental HCV NS5A inhibitor daclatasvir (BMS-790052) to pegylated interferon/ribavirin achieved undetectable viral load at 12 and 24 weeks, according to data presented at the at the 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011) last month in San Francisco.
Companies to Evaluate Daclatasvir plus TMC435 for Hepatitis C
- Details
- Category: HCV Treatment
- Published on Friday, 02 December 2011 00:00
- Written by Bristol-Myers Squibb
Bristol-Myers Squibb and Tibotec/Janssen announced that they will collaborate on the testing of an all-oral combination regimen for genotype 1 chronic hepatitis C consisting of daclatasvir (BMS-790052) plus TMC435; a clinical trial is expected to start in the first half of 2012.
Novel Compound Dissolves HIV on Contact, also Kills Hepatitis C Virus
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 29 November 2011 00:00
- Written by Texas A&M
While searching for agents active against hepatitis C virus (HCV), Texas A&M researchers discovered a small-molecule compound dubbed PD 404,182 that both inhibits HCV replication and destroys HIV on contact, according to a report in the November 14, 2011, advance online edition of Antimicrobial Agents and Chemotherapy.
AASLD 2011: All-Oral Combination of BI 201335, BI 207127 and Ribavirin Shows Good Efficacy at 12 Weeks
- Details
- Category: HCV Treatment
- Published on Thursday, 01 December 2011 00:00
- Written by Liz Highleyman
An interferon-free triple regimen containing the hepatitis C virus (HCV) protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127, and ribavirin for 12 weeks suppressed viral load in three-quarters of previously untreated genotype 1 patients, according to findings from the SOUND-C trials presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.
AASLD 2011: Predictors of Response to Boceprevir plus Pegylated Interferon/Ribavirin
- Details
- Category: HCV Treatment
- Published on Tuesday, 29 November 2011 00:00
- Written by Liz Highleyman
Low baseline viral load, hepatitis C virus (HCV) subtype 1b, and absent or mild liver damage predicted sustained response to treatment with boceprevir (Victrelis) plus pegylated interferon/ribavirin, researchers report at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this month in San Francisco.
More Articles...
- AASLD 2011: High Sustained Response Rates with PSI-7977 Plus Pegylated Interferon/Ribavirin
- AASLD 2011: TMC435 + Interferon/Ribavirin Raises Cure Rates for Naive and Experienced Hepatitis C Patients
- AASLD 2011: BI 201335 Performs Well with Standard Therapy
- AASLD 2011: HCV Direct-Acting Antivirals Boost Interferon Response Rates
Web Design and Development by